IP firm Sterne, Kessler, Goldstein & Fox recently brought together guests from pharma companies worldwide for two days to "Focus on Pharma: Creating, Protecting & Enforcing High-Value IP Assets." Here, director H. Keeto Sabharwal gives opening remarks discussing key objectives.
The conference focused on trends in substantive case law, their impact on patent prosecution and examination, and implications regarding the enforcement of patents in the pharmaceutical and biopharmaceutical industry. This panel discussed the ins-and-outs of pharmaceutical litigation.
The last time we saw this many Ph.D.s in one room was when we snuck into Paul Krugman's Nobel Prize celebration kegger. Sterne Kessler directors Marsha Rose Gillentine, Ph.D., Eric Steffe, and panelists discussed patent prosecution and the America Invents Act. Johnson & Johnson SVP of IP Policy & Strategy Philip Johnson gave the keynote. Other speakers included the firm directors Jorge Goldstein, Ph.D.; Paul Ainsworth; Dennies Varughese, Pharm. D.; Eldora Ellison, Ph.D.; Deborah Sterling, Ph.D.; Paul Calvo, Ph.D.; Timothy Shea Jr.; and Monica Riva Talley.
